

Functional characterization of a human POU1F1 mutation associated with isolated growth hormone deficiency: a novel etiology for IGHD

Marie-Laure Sobrier, Yu-Cheng Tsai, Christelle Pérez, Bruno Leheup, Tahar Bouceba, Philippe Duquesnoy, Bruno Copin, Daria Sizova, Alfredo Penzo,

Ben Z. Stanger, et al.

▶ To cite this version:

Marie-Laure Sobrier, Yu-Cheng Tsai, Christelle Pérez, Bruno Leheup, Tahar Bouceba, et al.. Functional characterization of a human POU1F1 mutation associated with isolated growth hormone deficiency: a novel etiology for IGHD. Human Molecular Genetics, 2016, 25 (3), pp.472-483. 10.1093/hmg/ddv486 . hal-01304122

HAL Id: hal-01304122 https://hal.sorbonne-universite.fr/hal-01304122

Submitted on 19 Apr 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	Functional characterization of a human POU1F1 mutation associated with isolated growth			
2	hormone deficiency (IGHD): a novel etiology for IGHD			
3				
4	Marie-Laure Sobrier ^{1*} , Yu-Cheng Tsai ² , Christelle Pérez ¹ , Bruno Leheup ³ , Tahar Bouceba ⁴ , Philippe			
5	Duquesnoy ¹ , Bruno Copin ⁵ , Daria Sizova ² , Alfredo Penzo ⁶ , Ben Z. Stanger ⁶ , Nancy E. Cooke ² ,			
6	Stephen A. Liebhaber ² , and Serge Amselem ^{1, 5} .			
7	¹ Inserm UMRS933, Hôpital Trousseau, Sorbonne Universités, UPMC Univ Paris 06, Paris, France			
8 9	² Department of Genetics, Perelman School of Medicine University of Pennsylvania, Philadelphia, USA			
10 11	³ Service de génétique clinique pédiatrique, Hôpital d'enfants, CHU Nancy, Vandoeuvre-Lès-Nancy, France			
12 13	⁴ Institut de Biologie Paris-Seine, Plateforme d'Intéractions Moléculaires Fr 3631, UPMC, Paris, France			
14 15	⁵ Service de Génétique et d'Embryologie Médicales, Assistance Publique-Hôpitaux de Paris, Hôpital Armand Trousseau, Paris, France			
16 17	⁶ Gastroenterology Division, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, Philadelphia, USA.			
18	Corresponding author:			
19	Marie-Laure SOBRIER			
20	UMRS933, Hôpital Trousseau, 26 avenue du Dr Netter, 75012 Paris, France			
21	Phone: 33 1 44 73 52 42			
22	Fax: 33 1 44 73 52 18			
23	e-mail: marie-laure.sobrier@inserm.fr			
24				

25 Abstract

26 POU1F1, a pituitary-specific POU-homeo domain transcription factor, plays an essential role 27 in specification of the somatotroph, lactotroph and thyrotroph lineages and in activation of GH1, PRL and $TSH\beta$ transcription. Individuals with mutations in POU1F1 present with combined deficiency of 28 29 GH, PRL, and TSH. Here we identified a heterozygous missense mutation with evidence of 30 pathogenicity, at the *POU1F1* locus, in a large family in which isolated growth hormone deficiency segregates as an autosomal dominant trait. The corresponding p.Pro76Leu mutation maps to a 31 32 conserved site within the POU1F1 transactivation domain. Bandshift assays revealed that the mutation 33 alters wild-type POU1F1 binding to cognate sites within the hGH-LCR and hGH1 promoter, but not to sites within the PRL promoter, and it selectively increases binding affinity to sites within the hGH-34 35 LCR. Co-immunoprecipitation studies reveal that this substitution enhances interactions of POU1F1 36 with three of its cofactors, PITX1, LHX3a and ELK1, and that residue 76 plays a critical role in these 37 interactions. Insertion of the mutation at the mouse *Poulfl* locus results in a dramatic loss of protein 38 expression despite normal mRNA concentrations. Mice heterozygous for the p.Pro76Leu mutation 39 were phenotypically normal while homozygotes demonstrated a dwarf phenotype. Overall, this study 40 unveils the involvement of POU1F1 in dominantly inherited isolated GH deficiency and demonstrates a significant impact of the Pro76Leu mutation on DNA binding activities, alterations in transactivating 41 functions and interactions with cofactors. Our data further highlight difficulties in modeling human 42 genetic disorders in the mouse despite apparent conservation of gene expression pathways and 43 44 physiologic functions.

45 Introduction

Pituitary development is temporally and spatially regulated by numerous signaling molecules and transcription factors (1). The Pou-homeodomain protein, Pou1f1, initially named Pit1, plays a key role in development of the anterior pituitary. Pou1f1 autoregulates its own expression (2, 3) and the expression of the three signature hormones [growth hormone (Gh), prolactin (Prl) and thyroidstimulating hormone beta subunit (Tsh β)]. As such, Pou1f1 serves essential functions in differentiation and proliferation of somatotropes, lactotropes and thyrotropes. The loss of POU1F1 functions results in combined pituitary hormone deficiency syndromes in both mice and humans.

53 The Poulf1 protein (291 amino acids) is composed of an N-terminal transactivating domain 54 (TAD) (4) involved in protein-protein interactions, and a homeodomain comprising Pou-specific and 55 Pou-Homeo domains involved in DNA binding and in interactions with transcriptional cofactors (2). 56 Poulf1 recognizes a weakly conserved A/T-rich consensus sequence (A/T)(A/T)TATNCAT, binds to 57 well-defined sites within the promoters and/or enhancers of multiple target genes (5, 6), and stimulates gene transcription in concert with a number of cofactors. Examples of Poulf1 interactions include the 58 59 association with Pitx1 via the Poulf1-TAD to activate the Prl and Gh promoters (7), and association 60 with the LIM domains of Lhx3 through the Poulf1-homeodomain to activate the Poulf1, $Tsh\beta$ and Prl promoters (8, 9) as well as the human *PRL* promoter (9). Importantly, forced co-expression of Poulf1 61 along with ELK1 (an ubiquitous transcription factor) is capable of activating the endogenous GH1 in 62 the human HEK293 cell line to levels 23-fold greater than measured in the non-transfected cells (10). 63 These studies highlight the central and essential functions of POU1F1 in anterior pituitary 64 65 development and in corresponding expression of three landmark hormones, GH, PRL and TSHB.

Naturally occurring mutations in *Poulf1* were initially reported in the Snell and Jackson mice, two dwarf strains with combined deficits in Gh, Tsh β and Prl associated with a hypoplastic anterior pituitary (11). In humans, the first *POU1F1* mutations were identified in 1992 (12) and 35 distinct mutations have since been reported worldwide (HGMD: hgmd.cf.ac.uk). The vast majority of these mutations act in a recessive manner with only six demonstrating an autosomal dominant inheritance of hormone deficiency. Although the detailed clinical attributes of patients with the various *POU1F1* 72 mutations can vary, these patients consistently display an overall picture of combined pituitary 73 hormone deficiency (CPHD) of GH, PRL, and TSH. GH and PRL deficiencies in affected individuals 74 are initially noted early in childhood, whereas the central hypothyroidism tends to appear later in 75 childhood or in adolescence. Radiologic imaging in these individuals often reveals a small anterior 76 pituitary gland with a normal posterior pituitary and infundibulum.

The human growth hormone cluster contains five genes; GH1 is expressed specifically in the 77 78 pituitary somatotropes while the expression of its four paralogs, GHV, CSA, CSB, and CSL (a 79 pseudogene), is specific to the syncytiotrophoblast epithelium lining the placental villi. This multigene 80 locus contrasts with the single Gh gene locus in the mouse. It was generated by local duplications of the ancestral GH gene at a point subsequent to the divergence of the rodent and primate lineages. The 81 82 GH1 promoter contains a pair of conserved POU1F1 binding sites within its proximal 200-bp region. In humans, these two sites (hereafter named prox-GH1 and prox-GH2) are not sufficient for high-level 83 expression of *GH1* in the pituitary when assayed in mouse transgenic assays (13). Instead, a powerful 84 enhancer, HSI, located 14.5 kb 5' to the hGH1 promoter, is both necessary and sufficient to drive high 85 86 levels of GH1 in the somatotrope. This HSI enhancer is a component of the hGH locus control region 87 (LCR) and does not appear to have a correlate in the mouse genome. HSI contains a tightly packed array of three POU1F1 binding sites (HSI-A, HSI-B and HSI-C). These three sites play an essential 88 89 role in both the activation and the maintenance of hGH1 transcription in the somatotrope (14–17) and 90 in its maintenance in the adult (18). POU1F1 binding at these LCR sites within HSI triggers the 91 formation of an extensive (32kb) domain of histone acetylation throughout the hGH locus (19) and is 92 essential for bringing the LCR in close proximity ("looping") to the hGH1 promoter (20–22). It has 93 been demonstrated that a single base difference between POU1F1 binding sites at the hGH1 promoter 94 and those at HSI modifies the conformation of the POU1F1/DNA complex suggesting that these 95 complexes may function through differential cofactor recruitment (23). Thus POU1F1 appears to have distinct functions in binding to its cognate sites at HSI and within the hGH1 promoter. 96

Here we describe a family in which nine members in three generations manifest growth
retardation linked to isolated growth hormone deficiency (IGHD). These individuals lack evidence for
associated TSH and PRL deficiency. This phenotype was inherited in an autosomal dominant pattern

and co-segregated over three generations with a missense mutation within the POU1F1 transcriptional
 activation domain. A series of *in vitro* and *in vivo* functional assays were carried out to delineate the
 mechanism(s) underlying this novel dominantly-inherited isolated GH deficit.

103 **Results**

104 Identification of a short stature phenotype inherited in an autosomal dominant pattern over 105 three generations of a human kindred

106 Nine individuals (5 females and 4 males) from the same non-consanguineous Caucasian 107 family originating from the east of France demonstrated findings of severe growth retardation. The 108 short stature phenotype segregated as an autosomal dominant trait over three successive generations. Height standard deviation (SD) scores, at the time of diagnosis, varied from -3 to -5.4 (Fig. 1A) and all 109 patients had a serum GH peak below $5\mu g/L$ (Table 1). The endocrine deficit was limited to a 110 deficiency in growth hormone (i.e. IGHD phenotype) (Table 1). Although basal serum PRL was 111 112 relatively low in affected individual III.7, the TRH stimulation induced a five-fold increase suggesting 113 that PRL expression and regulation was not adversely affected. Eight of the affected individuals (II.2, II.4, II.6, II.8, II.10, III.1, III.4 and III.7) benefited from a GH treatment with significant augmentation 114 in linear growth (the 9th individual, I.2, was not treated due to advanced age). 115

Magnetic resonance imaging (MRI) of the pituitary region performed in three affected members of the family was found to be normal in one case (III.7) and showed anterior pituitary hypoplasia for two individuals (III.1 and III.4); no abnormalities at the level of posterior pituitary, pituitary stalk, septum pellucidum, corpus callosum or optic nerves were detected. These data allowed us to conclude that a mutation resident in this kindred resulted in an isolated GH deficiency segregating as an autosomal dominant trait.

122 Affected individuals in the kindred carry a novel mutation at the *POU1F1* locus

123 The low levels of *hGH1* expression in the 9 short stature individuals and the hypoplasia of the 124 anterior pituitary in 2 of 3 studied, prompted us to screen for mutations in a defined set of genes 125 critical to GH synthesis and/or pituitary development; *GH1*, *LCR-GH1* (*HSI* fragment), *GHRHR*,

GHRH, GHSR, GHRL and HESX1 genes (see Methods for details). The sequence of each of these 126 target genes was normal. Causes of developmental defects of the pituitary were next assayed by 127 128 analysis of the PROP1 and POU1F1 genes in individual III.4. While PROP1 analysis revealed a normal sequence, the analysis of POU1F1 revealed heterozygosity for a sequence variant in exon 3, 129 c.227C>T (Fig. 1B). This base transition, not previously described in ExAC (exac.broadinstitute.org) 130 or in Ensembl (ensembl.org), results in a non-conservative substitution that replaces Proline by 131 132 Leucine at codon 76. This Pro76Leu (P76L) substitution maps within the highly conserved transcriptional activation domain (TAD) and involves a proline residue that is invariant in vertebrates 133 spanning evolution from zebrafish to primates (Figs. 1C, 1D). To establish its intra-familial 134 135 segregation, the region of the POU1F1 gene encompassing the mutation (exon 3) was subsequently sequenced in all available family members. This analysis revealed a perfect segregation of the defined 136 mutation with the short stature phenotype (Fig. 1A). These data lead us to conclude that the 137 dominantly inherited IGHD in this family was due to the defined c.227C>T at the POU1F1 locus. 138

139 Nuclear localization of the POU1F1 transcription factor is unaffected by the P76L mutation

To assess the functional consequences of the P76L mutation at the protein level, we first 140 assessed the subcellular distribution of the mutant POU1F1 protein. Expression plasmids encoding HA 141 tagged versions of the WT and the P76L POU1F1 proteins (pcDNA4-POU1F1_WT-HA and 142 143 pcDNA4-POU1F1_P76L-HA, respectively) were individually transfected into the human embryonic kidney cell line, HEK293T. Protein accumulation was assessed in individual cells by 144 145 immunofluorescence microscopy with an anti-HA antibody (Fig. 2A). The analyses of both the WT 146 and the mutant POU1F1 proteins revealed intense nuclear staining. These data suggest that the 147 mutation fails to alter the nuclear import and retention of POU1F1.

148 The P76L POU1F1 mutation has a negative impact on transcriptional activation of the *GH* gene

The functional impact of the P76L mutation on POU1F1 transcriptional activity was assessed in a luciferase reporter assay. The luciferase ORF was placed under the transcriptional control of the *hGH1* promoter (containing two well described POU1F1 binding sites) linked to the 404-bp HSI fragment of the *hGH* LCR encompassing an array of three critical POU1F1 binding sites (Fig. 2B,

top). The reporter plasmid was co-transfected into HEK293T cells along with a plasmid expressing the 153 WT or the P76L POU1F1 protein. Western analysis of three independent studies revealed that the 154 155 mutant protein was expressed at levels equal to or greater than the WT POU1F1 (Fig 2B and data not 156 shown). The co-transfection with the WT POU1F1 protein increased luciferase reporter activity by 5fold over that of an empty vector. The transcriptional enhancement of the luciferase reporter by the 157 P76L POU1F1 was 50% relative to the WT (Fig 2B). It was additionally noted that co-transfection of 158 159 equal amounts of the plasmid encoding the POU1F1 proteins did not inhibit the transcriptional activity associated with the wild-type POU1F1 protein (Fig 2C). These data lead us to conclude that the P76L 160 POU1F1 mutation results in a decrease in transcriptional activity of the GH gene, but argue against a 161 dominant effect of the mutant protein, at least in the context of defined reporter assay. 162

POU1F1_P76L has a differential impact on POU1F1 binding to cognate sites at HSI of the *hGH*LCR and at the *GH1* promoter

The decreased transcriptional capability of POU1F1_P76L prompted us to compare the 165 166 binding affinity of the WT and mutant POU1F1 protein towards a subset of cognate binding targets. This was done by subjecting bacterially generated WT and P76L POU1F1 proteins to surface plasmon 167 resonance (SPR) analysis. For purposes of the analysis, the WT and mutant proteins were generated in 168 parallel with all culture and purification steps held constant. Of note, we observed a 40-fold higher 169 170 recombinant protein yield from the bacterial cultures expressing the WT vs the mutant protein. This difference appeared to reflect the formation of inclusion bodies in cultures of the mutant protein 171 because the yield of the mutant protein was increased by culturing at lower temperature. This 172 difference in solubility is consistent with an altered conformation of the POU1F1_P76L protein. 173 174 Biotinylated DNA targets representing the defined POUF1 binding sites of the hGH1 promoter and of 175 HSI were immobilized on a streptavidin (SA) sensor chip and used for the analysis.

For a first qualitative test, equal amounts of the purified recombinant POU1F1_WT and POU1F1_P76L proteins (quantified by Experion; see Methods) were then loaded as analytes. The recorded resonance units (RU) showed that the WT and P76L POU1F1 proteins bind the promoter and the HSI DNA targets; the difference of 11RU on HSI target is significant. This result allows us to 180 conclude that POU1F1_P76L binds better than POU1F1_WT at the same concentration under our 181 assay conditions (Fig. 3A). As a control, we performed similar experiments with a recombinant form 182 of POU1F1 carrying a previously identified CPHD missense mutation (24). This mutation in a 183 conserved residue of the homeodomain abolishes the binding of POU1F1 to its DNA targets 184 demonstrated by a dramatic loss of binding in our SPR analysis (Fig 3A).

We next evaluated the affinity of the WT and the P76L proteins for their DNA targets in a set 185 186 of kinetic binding studies (see Methods). The dissociation constants obtained on the GH1 promoter measured using various concentrations of those proteins were similar for the POU1F1_WT and the 187 POU1F1 P76L proteins (Kd of 1.7x10⁻⁸M and 2.4x10⁻⁸M, respectively) (Fig. 3B, right panel). In 188 contrast, the Kd of the POU1F1_P76L protein was significantly lower than that of the wild-type 189 protein (i.e. 2.0x10⁻⁷M vs 2.0x10⁻⁶M) when tested for interaction with HSI (Fig. 3B, left panel). This 190 increased affinity of the POU1F1_P76L protein for the HSI sites was linked to an increased 191 association rate: $ka=5.9\times10^2$ mole⁻¹s⁻¹ for the POU1F1 WT and $ka=3.0\times10^3$ mole⁻¹s⁻¹ for the 192 POU1F1_P76L protein. These kinetic studies show that the WT POU1F1 protein has higher affinity 193 194 on the promoter sites than on the HSI sites. These data lead us to conclude that the P76L mutation has a differential impact on the interaction of the POU1F1 protein with different sets of cognate binding 195 196 sites.

POU1F1_P76L alters the binding of the POU1F1 WT protein at cognate sites in the *GH1* but not *PRL* promoter

199 We next compared by EMSA the binding of the WT alone, the POU1F1_P76L alone, and a mix of the two proteins, as would occur in individuals heterozygous for the P76L mutation. Binding 200 201 was assessed for DNA fragments containing the full set of POU1F1 binding sites (HSI and GH1 promoter) or each of the corresponding individual POU1F1 binding sites (HSI-A,B,C and prox-GH1, 202 203 prox-GH2). Remarkably, the migration patterns were different for the DNA incubated with 204 POU1F1_WT (lane 2), POU1F1_P76L (lane 3) and the mix of these two proteins (lane 4) for the HSI 205 (Fig. 4A-D) and for the hGH1 promoter sites (Fig. 4E-G). These data suggest a modified binding 206 conformation of the WT/mutant dimer (POU1F1_WT/POU1F1_P76L) complex on all POU1F1

binding sites of the *GH1* promoter and HSI. Of note, the POUF1_WT/POU1F1_P76L mix showed the
same migration pattern as POU1F1_WT when assayed for binding to the prolactin promoter (i.e. *PRL- 1* and *PRL-2*) (Fig. 4H, I). These data are consistent with the disease phenotype characterized by a
deficit in GH with no PRL deficiency.

The P76L mutation increases the interaction of POU1F1 with three different POU1F1 transcriptional cofactors

213 The impact of the POU1F1 mutation on complex formation with two pituitary-specific (PITX1 214 and LHX3a) transcriptional cofactors and one ubiquitous transcription factor (ELK1) was assessed by co-immunoprecipitations after cotransfection in HEK293T cells of an expression plasmid encoding the 215 216 HA-tagged POU1F1_WT or POU1F1_P76L with a plasmid encoding PITX1, LHX3a or ELK1. 217 Nuclear proteins were immunoprecipitated with an anti-HA antibody and the pellets were 218 subsequently assayed for each cofactor by western blot (Fig. 5, left panel). In parallel the nuclear 219 proteins were also immunoprecipitated with antibodies directed against each cofactor and the western 220 blots were revealed with an anti-HA-antibody (Fig. 5, right panel). The data revealed that the P76L mutation enhances complex formation with each partner by 5 - 10 folds when compared to the WT 221 POU1F1 protein (Fig. 5A, 5B, 5C). A formal possibility is that the difference in amount of complex 222 observed is due to the POU1F1_P76L conformational difference which would make the protein 223 224 complex more accessible the HA-tag to antibody. Co-immunoprecipitations performed with antibodies 225 directed against each of the interacting proteins allowed us to rule out this possibility.

226 To further evaluate the importance of the peptide surrounding Pro76 in these interactions, we performed similar co-immunoprecipitation experiments with different POU1F1 mutants in which 227 228 Pro76 and the neighboring (Leu74, Thr75, Cys77 and Leu78) were each individually replaced by alanine residues. The amount of complex formed with PITX1 and LHX3a (Fig. 6A and 6B, 229 respectively) was increased most prominently by the P76A and P76L substitutions. Moreover, with 230 231 ELK1 cofactor (Fig. 6C), the leucine substitution seemed to have a critical impact since an alanine did 232 not modify the amount of complex formed. These data demonstrate a major role of the Pro76 residue 233 in the interaction of the POU1F1 trans-activating domain with at least three partners.

A mouse model of the P76L mutation confirms the adverse impact on gene expression but fails to recapitulate the dominant inheritance pattern

236 To study the functional consequences of the P76L mutation in an in vivo context, we introduced the P76L mutation into the mouse Poulfl locus (see Methods and Fig. 7A). The expression 237 of P76L encoding Poulfl mRNA was confirmed in the pituitaries of P76L/wt mice and the mRNA 238 from the mutant allele was shown to be expressed at equivalent levels to the WT allele by a 239 240 comparative RT/PCR (Fig. 7B). Remarkably, however, the expression of the mutant Poulf1_P76L protein was markedly suppressed, with steady state levels in the mouse pituitary less than 10% of 241 output from the endogenous WT locus (Fig. 7C, asterix). The expression of mRNA from each of three 242 243 endogenous Poulf1-dependent genes (mGh, mPrl, mTsh) were assessed and found to be unaltered in mice heterozygous for the P76L mutation (data not shown). Similarly, the expression of the hGH1244 gene from the hGH/BAC transgene in the P76L heterozygous mouse was expressed at normal levels 245 (data not shown). Consistent with the low level expression of Poulf1 from the mutant locus, mice 246 247 homozygous for the P76L mutation displayed a dwarf phenotype (Fig. 7D). Overall, these data point 248 to a defect in steady state expression of the P76L mutant Poulf1 protein. This deficiency in protein expression is consistent with the poor yield of recombinant protein in the bacterial cultures and may 249 250 reflect a major alteration in protein solubility or stability in vivo.

251 Discussion

252 POU1F1 is essential for the formation of the somatotrope, lactotrope, and a subset of the thyrotrope lineages. As such, all *POU1F1* mutations thus far reported are linked to combined pituitary 253 254 hormone deficiency (CPHD) comprising decreases in expression of GH, PRL and TSH (25). In the current study, we report the first example of a POU1F1 mutation that is linked to an isolated GH 255 deficiency. Functional data reveal that the P76L mutation, located in a highly conserved segment of 256 the transcriptional activation domain (TAD), impacts on the binding patterns of POU1F1 and on the 257 258 interaction of POU1F1 with protein partners. The predicted conformational change induced by the 259 non-conservative substitution of a proline for a leucine is consistent with the low steady state levels of the mutant protein in the mouse despite normal levels of mRNA synthesis. Thus the P76L missense
mutation results in an unusual situation: a specific disruption of the human *GH1* gene expression.

262 Several lines of evidence demonstrate that the P76L variation identified in POU1F1 is a disease-causing mutation. First, the strict co-segregation of the phenotype with this mutation in 9 263 individuals over 3 generations. Second, the transcriptional activity of the POU1F1_P76L on the 264 chimeric LCR-hGH1 promoter is significantly lower than that of POU1F1_WT. Third, using SPR 265 266 assays, we show that the P76L mutation leads to an increased affinity of POU1F1 for the LCR sites. Fourth, bandshift assays reveal that the DNA binding pattern of a mix of POU1F1_WT and 267 268 POU1F1 P76L is different from that of POU1F1 WT alone on all five cognate binding sites in the 269 hGH LCR and GH1 promoter but not on the two cognate sites in the PRL binding sites. Fifth, as 270 shown by co-immunoprecipitation studies, the P76L mutation increases the interaction of POU1F1 with three of its known cofactors: PITX1, LHX3a and ELK1. 271

A predicted impact of the POU1F1_P76L mutation on conformation is consistent with the noted low yield of the mutant protein compared to the WT protein in two distinct settings; in E. Coli and in mice carrying the heterozygous *Pou1f1* mutation. It should be noted, however, as a formal possibility that the low protein expression in the mouse model may be contributed to by the presence of the myc epitope tag which was present at the mutant locus but not at the wt *Pou1f1* locus.

277 Noteworthy, two additional missense mutations have been identified in the human POU1F1 278 TAD, P14L (26) and P24L (27). Both of these mutations result in a dominantly inherited form of 279 pituitary deficit. However, in both cases, the patients displayed a classical CPHD phenotype rather 280 than the isolated GH loss currently being reported. The mutation site within the TAD, therefore 281 appears critical in terms of phenotypic consequences. The 3D-structure of the POU1F1 TAD remains undefined and *in silico* modeling could not be performed to test the relative impacts of the P76L, P14L 282 283 and P24L mutations on the three dimensional structure. Of note, however, all three of these constitute a non-conservative substitution of proline for leucine that is predicted to have a major impact on 284 285 protein secondary structure and tertiary folding.

Our attempt to model the P76L mutation in the mouse was informative in a number of respects. This mutation once introduced into the mouse *Poulfl* locus had no adverse effect on the 288 level of mRNA generated from the locus. Notably however, the steady level of mutant protein expressed from the P76L locus was markedly suppressed. Mice heterozygous for the mutation had no 289 290 appreciable decrease in size while mice homozygous were markedly dwarfed. Thus this mutation 291 results in a recessive dwarf phenotype in the mouse rather than the dominantly inherited phenotype in the human kindred, for which, haploinsufficiency cannot be the mechanism underlying the dominant 292 expression of the disease phenotype since the heterozygous parents of patients with homozygous 293 294 POU1F1 null mutation have a normal phenotype. Our in vitro data on the coexpression of the mutant 295 and wild-type POU1F1 proteins argue against a dominant negative effect of the mutant protein over 296 the wild-type.

297 The data favors a hypothesis of a toxic gain of function associated with the P76L mutation in humans for two reasons. First, the POU1F1_P76L protein binds the LCR sites with an increased 298 299 affinity, as compared to POU1F1_WT; this affinity difference might disrupt POU1F1_WT DNA 300 binding at the LCR target sites in heterozygous patients. It is therefore tempting to speculate that the 301 mutation could result in a higher occupancy at hGH LCR target sites precluding the binding of 302 POU1F1_WT. Second, we observed that the P76L mutation increases the interactions with three different cofactors. The mutant protein might therefore titrate POU1F1-interacting proteins leading to 303 a competition with the wild-type POU1F1 protein. Moreover, co-immunoprecipitation-alanine-304 305 scanning experiments revealed that the amino acid 76 precisely is critical for these interactions; the 306 weak equilibrium of the hGH1 transcriptional complex should be modified through the ability to recruit somatotrope specific cofactors necessary for high GH1 transcriptional level. Our data in 307 308 bandshift assays on the *PRL* promoter target sites are fully in accordance with the phenotype of the 309 patients with the P76L mutation who had no prolactin deficiency.

Of particular interest is the finding that the POU1F1_WT binds more tightly to promoter sites than those within the *LCR*. Previous studies have demonstrated that POU1F1 occupies its cognate sites in the *hGH1* promoter and at HSI of the *hGH LCR* with distinct conformations reflecting a single base pair difference (23). Thus the missense mutation at position 76 could differentially impact on POU1F1 actions at the *hGH* promoter *via* alterations of HSI function. Such alterations could explain the specific impact of the mutation on the human *hGH* gene as the *mGh* gene is lacking the HSI enhancer and the 316 *PRL* the *TSH* β and the *POU1F1* genes are not known to have corresponding LCR control 317 determinants.

In conclusion, the P76L mutation, which segregates perfectly with the severe growth retardation, involves a conformation modification of the POU1F1 protein that affects cofactors and DNA interactions that impact specifically the *hGH1* transcriptional level of expression. This constitutes a novel mechanism underlying a dominant form of IGHD in humans, also suggesting that POU1F1 gene should be screened for this phenotype.

323

324 Materials and methods

325 Patients

All individuals studied in the reported kindred provided their written informed consent to perform genetic studies. All were referred to the pediatric endocrinology outpatient clinic of the Nancy Medical School hospital (CHU of Nancy). Clinical details were assessed using an information sheet established by our laboratory.

330 Hormonal investigations and magnetic resonance imaging (MRI)

GH plasma values were evaluated after pharmalogical stimulations by arginine and ornithine, prolactin level before and after TRH stimulation, total and free T4 levels, all were measured according to methods at the time of diagnosis. Pituitary MRI was performed on a 0.5T General Electrics MR max instrument.

335 Mutation search

Genomic DNA was isolated from blood samples obtained from each individual using standard technique. All coding exons and intron-exon boundaries of the *GH1*, *LCR-GH1* (AF_010280), *GHRHR*, *GHRH*, *GHSR*, *GHRL*, *HESX1*, *PROP1* and *POU1F1* (NM_000306) genes were amplified using sets of primers available on request. Sequences were performed according to the thermal cycle sequencing Big dye terminator protocol (ABI Prism 310 Genetic Analyser, PerkinElmer Applied Biosystems).

342 Plasmid constructs

The full-length *POU1F1*, and *LHX3a* cDNAs (9) were subcloned into the pcDNA4 or pcDNA3 expression vectors in which HA or Flag tags were inserted in C-terminal, respectively. The *PITX1* cDNA, amplified from pituitary cDNA (Clonetech), was cloned into pcDNA3. The *ELK1* cDNA was subcloned from pCGN-ELK1 (Addgene, 27156) into pcDNA3 containing a tag Flag in C-terminal. The QuikChange Site-Directed Mutagenesis Kit (Stratagene) was used to generate plasmids encoding

different POU1F1 mutants, pcDNA4-POU1F1-HA-(P76L, L74A, T75A, P76A, C77A, L78A).

The luciferase reporter plasmid was constructed as follows: 406bp of the *LCR* (HSI, including the three POU1F1 target sites, AF_010280) and 494bp of the promoter (including the two POU1F1 binding sites) were linked after amplification using compatible restriction enzyme sites and subcloned into the pGL3-basic-Luciferase plasmid (Promega) to obtain pGL3-chimer[LCR-promGH] plasmid (Fig. 2B).

354 Cell culture and transfection

HEK293T cells, obtained from the American Type Culture Collection (Manassas, VA), were grown at
37°C in DMEM (Invitrogen), with 10% fetal calf serum. All transfections were performed at 60%
confluence using the Fugene method (Promega) according to the manufacturer's protocol.

358 Luciferase activity assays and western blot

359 HEK293T cell extracts were prepared and assayed for luciferase activity, using the Promega assay system, 48h after co-transfection of the pGL3-chimer[LCR-promGH] reporter gene (100ng) together 360 with either the empty pcDNA3 expression vector and/or the POU1F1-cDNA WT and/or mutant 361 362 pcDNA4 constructs at different amounts. Each transfection experiment was carried out in triplicate and was independently replicated at least three times. Cell extracts were separated on a 10% 363 polyacrylamide gel, then transferred to a nitrocellulose membrane and probed with an anti-POU1F1 364 polyclonal antibody (sc-16288, Santa Cruz Biotechnology) and an anti-αβtubulin polyclonal antibody 365 (2148, Cell Signaling). 366

367 Protein purification

The full-length POU1F1 cDNA was cloned at the BamHI NotI sites into the pGEX-6P-1 vector (GE 368 Healthcare) including a PreScission protease site to remove the GST tag. GST-tagged fusion proteins 369 370 were produced in the BL21 DE3 star strain of Escherichia coli (Invitrogen). After induction for 3 h with 0.5 mM isopropyl-β-d-thiogalactopyranoside at 37°C for the GST-POU1F1_WT, at 25°C during 371 4h for the GST-POU1F1_P76L, at 15°C for 4h for the GST-POU1F1_R265W, the bacterial pellet was 372 freezed/thawed 3 times followed by sonication in PBS1X (200 ml/L of culture), 1% Triton X-100, 373 374 10% glycerol and 1mg/ml lysozyme and finally clarified by centrifugation at $22.000 \times g$ for 20 min. 375 Supernatants were incubated 30mn at room temperature with glutathione-Sepharose beads (GE Healthcare), then washed 4 folds in PBS1X. The last wash was performed in cleavage buffer (50mM 376 Tris-HCl pH7.0, 150mM NaCl, 1mM EDTA, 1mM PMSF), then beads were incubated 4h at 4°C with 377 378 600µl of PreScission protease (1U/µl, GE Healthcare) in 40ml of a cleavage buffer. Centrifugation of 379 beads at 500g 15mn at 4°C allowed to collect soluble purified protein which is concentrated on 380 Corning Spin-X UF 20ml, 10000 MWCO. Two to 5ml of protein were dialyzed in HBS buffer (10mM HEPES pH7.4, 150mM NaCl, 3 mM EDTA) overnight. All preparations of proteins were checked on 381 382 Experion (BioRad) instrument for their quality and quantification.

383 Surface Plasmon Resonance analysis

Real-time DNA-protein interaction assays were performed using a Biacore 3000 instrument controlled 384 385 by Biacore 3000 Control Software v4.1 (GE Healthcare). All experiments were done at 25°C. After preincubation in 1M NaCl, 50mM NaOH for 1min (3 times), 75µl of 500nM biotinylated DNA was 386 covalently coupled to a streptavidine (SA) sensor chip (GE Healthcare) (5µL/min) in HBS-EP running 387 buffer [10 mM Hepes (pH7.4), 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20]. The chip was 388 389 then washed 1min (5µL/min) with 1M NaCl, 50mM NaOH. Real-time monitoring was displayed in a 390 sensorgram as the resonance unit (RU) versus time (s). The 70-bp fragment of the GH1 promoter (two 391 POU1F1 binding sites) was generated by annealing a sense (5' biotinylated) and antisense 392 oligonucleotide and 900RU were obtained. A 212-bp PCR product corresponding to the HSI (three 393 POU1F1 binding sites) was amplified from genomic DNA using a biotinylated primer and 1900RU were anchored. Binding studies were performed during 5min with 25µl of 50nM purified protein in 394

HBS-EP, 1mM MgCl2. The chip surface was regenerated using 0.1%SDS (flow rate: 30μ /min; contact time: 30s). Kinetic studies were performed at least in triplicate. Defined concentrations (from 0 to 50nM) of POU1F1 proteins were injected with a 5min association phase and 8min dissociation phase and their dose dependency response was measured. Data were analysed with BIAevaluation software 4.1 and the Kd dissociation constant was determined using the Fit kinetic simultaneous K_A/K_D (1:1 binding; Langmuir algorithm) and validated when the Chi2 was <10 (this value means that the model used for fitting adequately describes the data).

402 Subcellular localization

403 HEK293T cells were seeded at 50% confluence on a strip into each chamber of a six-chamber tissue 404 culture plate. After transfection of pcDNA4-POU1F1_WT-HA or pcDNA4-POU1F1_P76L-HA, cells 405 were fixed 24h in 4% paraformaldehyde and permeabilized in PBS1X-Triton 0.1%. Slides were then 406 blocked with PBS1X-Triton 0.1%-BSA10% and incubated with an anti-HA mouse monoclonal 407 antibody (Sigma) (1/1000) for 1h. The strips were washed and incubated with the Alexa488-goat anti-408 mouse secondary antibody (Invitrogen) (1/2000) for 1h. Nuclear counterstaining was performed with Vectashield containing 4',6-diamidino-2-phenyllindole dihydrochloride (DAPI) (Vector Laboratories). 409 410 Immunostaining was then visualized on a Nikon eclipse 80i microscope, and images were captured 411 using a Qimaging (Retiga 2000R) camera and Image Pro Express 6.0 software.

412 Co-immunoprecipitation

HEK293T cells (3x10⁶) were transfected with 1.5µg of pcDNA4-POU1F1 WT-HA or of pcDNA4-413 POU1F1 P76L-HA- plasmids and 1.5µg of one of the plasmid encoding the cofactor tested (pcDNA3-414 415 PITX1, pcDNA3-LHX3a-Flag or pcDNA3-ELK1-Flag). Nuclear extracts prepared after 30h of expression were divided in two parts and incubated overnight with each antibody, using Universal 416 magnetic CoIp kit (Active Motif) following manufacturer's instructions. Purified proteins from 417 magnetic beads were then resolved by SDS-PAGE, immunoblotted, and revealed by 418 419 chemiluminescence (Supersignal West Dura Chemiluminescent Substrate, Pierce, Thermo Scientific). Quantity One 1D analysis software (Bio Rad) was used to visualize and to quantify (Volume 420

421 Rectangle tool) the complex formed between the two proteins: histograms represent protein422 immunoprecipitated/input protein expression ratios.

423 Electrophoretic Mobility Shift Assay (EMSA)

424 The LightShift Chemiluminescent EMSA kit (Pierce) was used for the study. 20 fmoles of different Biotin end-labeled DNA duplexes (promGH1 70bp, HSI 212bp, prox-GH1 32bp, prox-GH2 30bp, 425 HSI-A 37bp, HSI-B 37bp, HSI-C 38bp, PRL1 (=3P) 29bp, PRL2 (=1P) 29bp (23) were incubated for 426 20mn at room temperature with 200ng of POU1F1 purified proteins. The DNA-protein complexes 427 428 were subjected to a 5% or 6% native polyacrylamide gel electrophoresis and transferred using the 429 PierceG2 Fast-blotter system (Thermo-Scientific) to a nylon membrane (Biodyne B, Pierce). After 430 transfer, the membrane was immediately cross-linked (UV Stratalinker 2400, Stratagene) using 431 autocrosslink program. A chemiluminescent method utilizing a luminol/enhancer solution and a stable 432 peroxide solution (Pierce) was used as described by the manufacturer.

433 Mouse model

The P76L mutation was introduced into the mouse genome *via* standard homologous recombination in
mouse ES cells. The recombinant ES cells were validated for the presence of the corresponding
introduced single nucleotide substitution as well as the presence of the Neo^R selection marker and Myc
epitope tag by direct sequencing of the *Poulfl* locus of an adult wt/P76L mouse tail DNA. The Neo^R
cassette, flanked by a unidirectional set of LoxP sites, was deleted by crossing the mouse with a EIIACre mouse. The final mutant gene was validated by multiple targeted PCR and sequence analyses.

440

441 Acknowledgments

442 We thank all patients and family members for their cooperation.

443 The work was supported by INSERM

444 **Conflict of interest statement:** none declared

446 **References**

- 447 1. Rizzoti,K. (2015) Genetic regulation of murine pituitary development. *J. Mol. Endocrinol.*, 54,
 448 R55–73.
- 2. Andersen,B. and Rosenfeld,M.G. (2001) POU domain factors in the neuroendocrine system: lessons
 from developmental biology provide insights into human disease. *Endocr. Rev.*, 22, 2–35.
- 3. Ho,Y., Cooke,N.E. and Liebhaber,S.A. (2015) An autoregulatory pathway establishes the definitive
 chromatin conformation at the pit-1 locus. *Mol. Cell. Biol.*, 35, 1523–1532.
- 4. Ingraham,H.A., Flynn,S.E., Voss,J.W., Albert,V.R., Kapiloff,M.S., Wilson,L. and Rosenfeld,M.G.
 (1990) The POU-specific domain of Pit-1 is essential for sequence-specific, high affinity
 DNA binding and DNA-dependent Pit-1-Pit-1 interactions. *Cell*, 61, 1021–1033.
- 456 5. Andersen, B. and Rosenfeld, M.G. (1994) Pit-1 determines cell types during development of the
 457 anterior pituitary gland. A model for transcriptional regulation of cell phenotypes in
 458 mammalian organogenesis. *J Biol Chem*, 269, 29335–8.
- 459 6. Savage, J.J., Yaden, B.C., Kiratipranon, P. and Rhodes, S.J. (2003) Transcriptional control during
 460 mammalian anterior pituitary development. *Gene*, **319**, 1–19.
- 7. Szeto, D.P., Ryan, A.K., O'Connell, S.M. and Rosenfeld, M.G. (1996) P-OTX: a PIT-1-interacting
 homeodomain factor expressed during anterior pituitary gland development. *Proc. Natl. Acad. Sci. U. S. A.*, 93, 7706–7710.
- 8. Bach,I., Rhodes,S.J., Pearse,R.V., Heinzel,T., Gloss,B., Scully,K.M., Sawchenko,P.E. and
 Rosenfeld,M.G. (1995) P-Lim, a LIM homeodomain factor, is expressed during pituitary
 organ and cell commitment and synergizes with Pit-1. *Proc Natl Acad Sci U A*, 92, 2720–4.

467	9. Sobrier, ML., Brachet, C., Vié-Luton, MP., Perez, C., Copin, B., Legendre, M., Heinrichs, C. and
468	Amselem, S. (2012) Symptomatic heterozygotes and prenatal diagnoses in a
469	nonconsanguineous family with syndromic combined pituitary hormone deficiency resulting
470	from two novel LHX3 mutations. J. Clin. Endocrinol. Metab., 97, E503–509.
471	10. Yang,X., Jin,Y. and Cattini,P.A. (2010) Appearance of the pituitary factor Pit-1 increases
472	chromatin remodeling at hypersensitive site III in the human GH locus. J. Mol. Endocrinol.,
473	45 , 19–32.
474	11. Li,S., Crenshaw,E.B. d, Rawson,E.J., Simmons,D.M., Swanson,L.W. and Rosenfeld,M.G. (1990)
475	Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-
476	domain gene pit-1. <i>Nature</i> , 347 , 528–33.
477	12. Radovick, S., Nations, M., Du, Y., Berg, L.A., Weintraub, B.D. and Wondisford, F.E. (1992) A
478	mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone
479	deficiency. Science, 257, 1115–8.
480	13. Jones, B.K., Monks, B.R., Liebhaber, S.A. and Cooke, N.E. (1995) The human growth hormone gene
481	is regulated by a multicomponent locus control region. Mol. Cell. Biol., 15, 7010–7021.
482	14. Bennani-Baïti,I.M., Asa,S.L., Song,D., Iratni,R., Liebhaber,S.A. and Cooke,N.E. (1998) DNase I-
483	hypersensitive sites I and II of the human growth hormone locus control region are a major
484	developmental activator of somatotrope gene expression. Proc. Natl. Acad. Sci. U. S. A., 95,
485	10655–10660.
486	15. Shewchuk, B.M., Asa, S.L., Cooke, N.E. and Liebhaber, S.A. (1999) Pit-1 binding sites at the
487	somatotrope-specific DNase I hypersensitive sites I, II of the human growth hormone locus
488	control region are essential for in vivo hGH-N gene activation. J. Biol. Chem., 274, 35725-
489	35733.

- 490 16. Su,Y., Liebhaber,S.A. and Cooke,N.E. (2000) The human growth hormone gene cluster locus
 491 control region supports position-independent pituitary- and placenta-specific expression in the
 492 transgenic mouse. *J. Biol. Chem.*, 275, 7902–7909.
- 493 17. Fleetwood,M.R., Ho,Y., Cooke,N.E. and Liebhaber,S.A. (2012) DNase I hypersensitive site II of
 494 the human growth hormone locus control region mediates an essential and distinct long-range
 495 enhancer function. *J. Biol. Chem.*, 287, 25454–25465.
- 496 18. Ho,Y., Shewchuk,B.M., Liebhaber,S.A. and Cooke,N.E. (2013) Distinct chromatin configurations
 497 regulate the initiation and the maintenance of hGH gene expression. *Mol. Cell. Biol.*, 33,
 498 1723–1734.
- 499 19. Ho,Y., Elefant,F., Cooke,N. and Liebhaber,S. (2002) A defined locus control region determinant
 500 links chromatin domain acetylation with long-range gene activation. *Mol Cell*, 9, 291–302.
- 20. Ho,Y., Tadevosyan,A., Liebhaber,S.A. and Cooke,N.E. (2008) The juxtaposition of a promoter
 with a locus control region transcriptional domain activates gene expression. *EMBO Rep.*, 9,
 891–898.
- 504 21. Yoo,E.J., Cooke,N.E. and Liebhaber,S.A. (2012) An RNA-independent linkage of noncoding
 505 transcription to long-range enhancer function. *Mol. Cell. Biol.*, **32**, 2020–2029.
- 506 22. Yoo,E.J., Brown,C.D., Tsai,Y.-C., Cooke,N.E. and Liebhaber,S.A. (2015) Autonomous actions of
 507 the human growth hormone long-range enhancer. *Nucleic Acids Res.*, 43, 2091–2101.
- 508 23. Shewchuk,B.M., Ho,Y., Liebhaber,S.A. and Cooke,N.E. (2006) A single base difference between
 509 Pit-1 binding sites at the hGH promoter and locus control region specifies distinct Pit-1
 510 conformations and functions. *Mol Cell Biol*, 26, 6535–46.
- 511 24. Turton, J.P., Strom, M., Langham, S., Dattani, M.T. and Le Tissier, P. (2012) Two novel mutations in
 512 the POU1F1 gene generate null alleles through different mechanisms leading to combined
 513 pituitary hormone deficiency. *Clin. Endocrinol. (Oxf.)*, **76**, 387–393.

514	25. Pfäffle,R. and Klammt,J. (2011) Pituitary transcription factors in the aetiology of combined
515	pituitary hormone deficiency. Best Pract. Res. Clin. Endocrinol. Metab., 25, 43-60.
516	26. Fofanova,O.V., Takamura,N., Kinoshita,E., Yoshimoto,M., Tsuji,Y., Peterkova,V.A.,
517	Evgrafov, O.V., Dedov, I.I., Goncharov, N.P. and Yamashita, S. (1998) Rarity of PIT1
518	involvement in children from Russia with combined pituitary hormone deficiency. Am. J.
519	Med. Genet., 77, 360–365.
520	
520	27. Onta,K., Nobukuni, Y., Mitsubuchi,H., Fujimoto,S., Matsuo,N., Inagaki,H., Endo,F. and Matsuda,I.
521	(1992) Mutations in the Pit-1 gene in children with combined pituitary hormone deficiency.
522	Biochem. Biophys. Res. Commun., 189, 851–855.

523

524 Legends to figures

525 Figure 1: Identification of a POU1F1 mutation segregating with a short stature phenotype and 526 low serum GH levels in a three generation kindred

A. Genealogical tree of the IGHD family. Squares, males; circles, females; filled black symbols,
IGHD patients. For subjects with growth retardation their height standard deviation (SD) is indicated
between brackets. The genotype (N/N: normal, N/M: heterozygous) is indicated under each tested
individual.

B. Electrophoregram of the portion of exon 3 showing (black arrow) the heterozygous c.227C>T
transition leading to p.Pro76Leu mutation. The vertical line represents the intron-exon junction.

C. Schematic representation of the *POU1F1* cDNA and POU1F1 protein: six exons encoding the 291
amino acids protein consisting of two main domains, the Transactivating Domain (TAD, orange) in
which the variation has been identified (noted with an asterisk) and the POU-S and POU-H domains
(homeodomain, purple).

D. Evolutionary conservation of proline 76 (noted above with an asterisk): interspecies similarity (shown in one-letter code) of the TAD domain of POU1F1 aligned with sequences of the TAD domain found in 9 other vertebrates species: black underlined, total conservation; grey underlined, conservative amino acid substitutions; not underlined, amino acid not conserved and indexed in a different group.

Figure 2: Conserved nuclear localization and diminished transcriptional activity of the mutant POU1F1 protein

A. Subcellular localization of POU1F1_WT and POU1F1_P76L in HEK293T cells transfected with
the corresponding HA tagged expression plasmids. 48 hours after transfection, cells were
immunostained with mouse anti-HA antibody (1/1000) then Alexa488 (goat anti-mouse 1/2000).
Nuclei are stained in blue by DAPI. The two proteins (wild-type and mutated) were both localized in
the nucleus. A control with no transfected cells is also shown.

B. Impact of the Pro76Leu mutation on the transcriptional capability of POU1F1. HEK293T cells
were co-transfected with pcDNA3-POU1F1_WT-HA or pcDNA3-POU1F1_P76L-HA in combination

with a luciferase reporter ORF under control of the HSI enhancer segment of the *hGH* LCR linked directly to the intact *hGH* promoter pGL3-chimer[LCR-promGH]. The previously-defined POU1F1 binding sites in HSI and in the *hGH* promoter are indicated by the red lines. POU1F1 protein expression from the expression vectors was monitored by western blot with anti-POU1F1 polyclonal antibody relative to $\alpha\beta$ tubulin level (top). Luciferase activity represents the means +/-SD of triplicate assays; a representative experiment of three experiments.

C. Assessment of a potential dominant negative effect of the P76L mutation over the WT protein. Cotransfection of the HSI/hGH/Luc reporter with the POU1F1_WT plasmid, POU1F1_P76L plasmid in increasing amounts up to a saturation response, or with a 1:1 mixture of the two plasmids.

560 Figure 3: POU1F1 binding to DNA studied by Surface Plasmon Resonance (SPR)

A. Sensorgrams. Biotinylated DNAs (*HSI* and prom*GH1*) were loaded on a streptavidin chip and
binding of 50nM of purified WT (blue) or P76L (green) or R265W (red) POU1F1 proteins to the two
DNA targets was assessed. The recorded resonance units (RU) for each protein were noted.

B. Kinetics of POU1F1 binding the DNA sites: 0, 10, 20, 30, 40 and 50nM of each purified protein were successively loaded on the streptavidin chips on which biotinylated DNA POU1F1 targets have been anchored. After data treatment using BIAevaluation software 4.1, the association and dissociation constants corresponding to a Kd value in molar (M) were determined for WT and P76L-POU1F1 proteins on each target sequence and represented by histograms: on the *HSI* (left graph) and on the h*GH1* promoter (right graph). Each study was performed in triplicate.

570 Figure 4: Analysis of POU1F1 binding to DNA by electrophoretic mobility shift assays

A. 20 fmoles of biotinylated DNA containing a 212-bp segment of HSI encompassing all three
POU1F1 binding sites (A, B, and C) were incubated with 200ng of purified WT (Lane 2) or mutant
P76L POU1F1 (Lane 3) protein or with a 1:1 mixture (100ng of each) of the two proteins (Lane 4).
Lane 1 contains the biotinylated DNA target in the absence of added protein.

575 **B-D**. Binding to each individual POU1F1 binding site within HSI. 37bp including one site HSI-A, B,

576 37bp *HSI-B*, C, 38bp *HSI-C*, D.

E. Binding to a 70-bp segment of the *GH1* promoter encompassing the two POU1F1 binding sites.

- F-G. Binding to each of the two POU1F1 binding sites in the h*GH1* promoter: 32-bp fragment
 encompassing prox-*GH1* (F) or the 30-bp fragment encompassing prox-*GH2* (G).
- 580 H-I. Binding to each of the two POU1F1 binding sites in the human *PRL* gene promoter. 29-bp
 581 fragments containing either *PRL-1* (H) or *PRL-2* (I).

582 Figure 5: Co-immunoprecipitation of WT and P76L POU1F1 proteins with three cofactors

583 HEK293T cells were co-transfected with plasmids pcDNA4-POU1F1-HA expressing POU1F1_WT or 584 P76L (lanes labeled WT and P76L, respectively) and with each of the following three expression 585 vectors: pcDNA3-PITX1 (A), pcDNA3-LHX3a-Flag (B) and pcDNA3-ELK1-Flag (C). Nuclear 586 extracts were co-immunoprecipitated with an anti-HA antibody and the western blots were revealed 587 with an anti-PITX1 antibody for PITX1 and an anti-Flag antibody for LHX3 and ELK1 (left panels). The same nuclear extracts were co-immunoprecipitated with an anti-PITX1 antibody for PITX1 and an 588 589 anti-Flag antibody for LHX3 and ELK1 and westerns blots revealed with the anti-HA antibody (right panels); IP: immunoprecipitation, WB: western blots. Quantification of the complex formed, 590 represented by histograms, was calculated as the ratio of protein immunoprecipitated to protein 591 592 expressed (input).

593 Figure 6: Co-immunoprecipitation POU1F1 with three cofactors. Interactions are compared 594 among the WT POU1F1 and a series of derived alanine substitutions surrounding proline 76 595 site.

- HEK293T cells were co-transfected with plasmids pcDNA4-POU1F1-HA expressing POU1F1_WT or
 L74A, T75A, P76L, P76A, C77A, L78A and pcDNA3-PITX1 or pcDNA3-LHX3a-Flag or pcDNA3ELK1-Flag. Co-immunoprecipitations were performed with an anti-PITX1 antibody (A) or Flag
 antibodies for LHX3a (B) and ELK1 (C) on nuclear extracts samples. Western blots were generated
 using an anti-HA antibody. Quantification of the complex formed, represented by histograms (right
 side), was evaluated as the ratio of protein immunoprecipitated to protein expressed (input).
- Figure 7: Introduction of the P76L mutation into the *Poulf1* locus in the mouse genome.

603 A. Homologous recombination at the *Poulfl* locus in the mouse genome. The native *Poulfl* locus 604 is shown on the top and the targeting vector used to insert the P76L mutation into the locus is shown 605 below. The initial recombination product is displayed on the third line and the final locus after deletion of the Neo^R cassette via Cre/Lox recombination is displayed at the bottom. The position of the 606 P76L mutation is denoted by the asterix, the dual selection cassettes, Neo^R and TK, are represented by 607 608 the labeled red rectangles, Lox sites are indicated by the arrowhead, and the positions of the primers 609 used for selective detection of the wt and mutant Poulf1 mRNAs are indicated and numbered below 610 the diagram.

611 B. mRNA expression from the PitP76L locus in the mouse pituitary. Top: Poulf1 mRNA 612 expression from the P76L locus was specifically detected in a mouse heterozygous for the mutant allele by an RT/PCR assay using a set of primers positioned at exon 2 (primer 1) and within the myc 613 614 epitope segment in exon 6 (specific to the mutant allele) (primer 2). Bottom: The relative levels of the mRNA expression from the wt and the mutant locus were directly compared in a mouse heterozygous 615 for the mutant allele (wt/P76L) and a wt mouse (wt/wt) by an RT/PCR analysis using the exon 5 616 617 primer (primer 3) and a primer within the 3' UTR (primer 4) in exon 4, bracketing the myc epitope tag 618 specific to the mutant locus.

619 **C. Protein expression from the P76L locus in the mouse pituitary.** Western blot of pituitary 620 extracts from wt/wt and wt/P76L mice were probed with antibodies to mouse Poulf1 (left blot) and 621 with an antibody to the myc epitope tag (specific to the mutant locus) (right blot). The overall level of 622 Poulf1_WT protein in the WT/P76L heterozygote pituitary is approximately half of that in the 623 WT/WT mouse. A faint band at the position of the mutant Pit1 protein (*) is migrating at the position 624 predicted from the Pit-1 protein containing the Myc epitope tag. The expression of the P76L Poulf1 625 protein was directly verified by re-probing the Western with an antibody to the myc epitope.

D. Growth curves of WT/WT, WT/P76L and P76L/P76L mice. The body weights are shown in the
Y-axis and the genotypes are indicted for each curve. The analyses of male (top) mice are shown. A
parallel analysis of females gave an identical result (not shown).

629

Patient	Height	GH	T4	PRL	GH	MRI
	SD				treatment	
I.2	-3.2	Not eval	Not eval	Not eval	-	-
II.2	-4.3	4	70	Not eval	+	-
II.4	-5.4	2.2/2.2	78	Not eval	+	-
II.6	-3	1.5/0.5	58	Not eval, normal	+	-
				breast feeding		
II.8	-4.7	2	94	Not eval	+	-
II.10	-4	3/0.5	<u>10.7</u>	Not eval, normal	+	-
				breast feeding		
III.1	-3.5	4.3/3.1	<u>10.4</u>	3.1 (12.5/TRH)	+	AP
						hypo
III.4	-3	2.4/2.3	<u>15.2</u>	5.1 (16.7/TRH)	+	AP
						hypo
III.7	-3.2	2/3.1	<u>11.9</u>	0.9 (4.6/TRH)	+	Ν

631

632 <u>Table 1</u> : Clinical and endocrinological data of the nine IGHD patients.

633 Height SD, height standard deviation; GH μ g/L: arginine /ornithine tests, normal value >10 μ g/L; total

T4 ng/ml: normal value 40-120 for II.2, II.4, II.6 and II.8 and <u>free T4 pmole/L</u> normal value 10-21 for

635 II.10, III.1, III.4 and III.7; PRL ng/ml, PRL before and after TRH stimulation (between brackets):

normal value 2.5-20. Not eval: not evaluated. AP hypo: hypoplasia of the anterior pituitary, N: normal.



B pGL3-chimer[LCR-promGH]













В



Lane 1: free probe Lane 2: probe+POU1F1_WT Lane 3: probe+POU1F1_P76L Lane 4: probe+POU1F1_WT+POU1F1_P76L

Figure 4







WB: POU1F1 revealed with anti-HA antibody







В



